{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": 2019
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset Parkinson’s disease (PD). LRRK2 contains leucine-rich repeats, a GTPase domain, a COR domain, a kinase and a WD40 motif.",
          "judgment": "Yes",
          "reasoning": "Paper clearly defines that LRRK2 mutations are linked to PD and describes the structure of LRRK2."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We undertook a KESTREL screen in rat brain extracts to identify proteins that were phosphorylated by an activated PD mutant of LRRK2 (G2019S).",
          "judgment": "Yes",
          "reasoning": "KESTREL screen effectively models the disease pathogenesis by identifying physiological substrates of LRRK2."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Only one of the mutations analyzed, namely G2019S, stimulated kinase activity. Four mutations inhibited LRRK2 kinase activity (R1941H, I2012T, I2020T and G2385R), whereas the remainder (R1441C, R1441G, Y1699C and T2356I) did not influence activity.",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type and mutant controls, and experiments were performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The G2019S mutation significantly stimulated LRRK2 autophosphorylation as well as phosphorylation of moesin, LRRKtide and MBP.",
          "judgment": "Yes",
          "reasoning": "Statistical analyses show significant enhancement of kinase activity by the G2019S mutation."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2019S mutation significantly enhances LRRK2 kinase activity, supporting its pathogenic role in Parkinson's disease."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": 1941
        },
        "variant_string_id": "LRRK2 R1941H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset Parkinson’s disease (PD). LRRK2 contains leucine-rich repeats, a GTPase domain, a COR domain, a kinase and a WD40 motif.",
          "judgment": "Yes",
          "reasoning": "Paper clearly defines that LRRK2 mutations are linked to PD and describes the structure of LRRK2."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We undertook a KESTREL screen in rat brain extracts to identify proteins that were phosphorylated by an activated PD mutant of LRRK2 (G2019S).",
          "judgment": "Yes",
          "reasoning": "KESTREL screen effectively models the disease pathogenesis by identifying physiological substrates of LRRK2."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Four mutations inhibited LRRK2 kinase activity (R1941H, I2012T, I2020T and G2385R), whereas the remainder (R1441C, R1441G, Y1699C and T2356I) did not influence activity.",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type and mutant controls, and experiments were performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Three mutations (R1941H, I2012T and G2385R) markedly inhibited LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "Statistical analyses show significant inhibition of kinase activity by the R1941H mutation."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R1941H mutation significantly inhibits LRRK2 kinase activity, suggesting its pathogenic role in Parkinson's disease."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": 2020
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset Parkinson’s disease (PD). LRRK2 contains leucine-rich repeats, a GTPase domain, a COR domain, a kinase and a WD40 motif.",
          "judgment": "Yes",
          "reasoning": "Paper clearly defines that LRRK2 mutations are linked to PD and describes the structure of LRRK2."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We undertook a KESTREL screen in rat brain extracts to identify proteins that were phosphorylated by an activated PD mutant of LRRK2 (G2019S).",
          "judgment": "Yes",
          "reasoning": "KESTREL screen effectively models the disease pathogenesis by identifying physiological substrates of LRRK2."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Four mutations inhibited LRRK2 kinase activity (R1941H, I2012T, I2020T and G2385R), whereas the remainder (R1441C, R1441G, Y1699C and T2356I) did not influence activity.",
          "judgment": "Yes",
          "reasoning": "The paper includes both wild-type and mutant controls, and experiments were performed in triplicate."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Another PD mutation, namely I2020T, decreased LRRK2 autophosphorylation and phosphorylation of MBP and moesin, but to a lower extent than the R1941H, I2012T and G2385R mutations.",
          "judgment": "Yes",
          "reasoning": "Statistical analyses show moderate inhibition of kinase activity by the I2020T mutation."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T mutation moderately decreases LRRK2 kinase activity, suggesting its potential pathogenic role in Parkinson's disease."
    }
  ]
}